Loading…

Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics

mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely...

Full description

Saved in:
Bibliographic Details
Published in:Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2024-09, Vol.16 (5), p.e1992-n/a
Main Authors: Jiao, Xiangyu, He, Xi, Qin, Shugang, Yin, Xiaoling, Song, Tingting, Duan, Xing, Shi, Haixing, Jiang, Shanhui, Zhang, Yupei, Song, Xiangrong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33
container_end_page n/a
container_issue 5
container_start_page e1992
container_title Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
container_volume 16
creator Jiao, Xiangyu
He, Xi
Qin, Shugang
Yin, Xiaoling
Song, Tingting
Duan, Xing
Shi, Haixing
Jiang, Shanhui
Zhang, Yupei
Song, Xiangrong
description mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Biology‐Inspired Nanomaterials > Lipid‐Based Structures LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.
doi_str_mv 10.1002/wnan.1992
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3112530164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120330530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</originalsourceid><addsrcrecordid>eNp10E1LwzAYB_AgipvTg19ACl700C0vbdocx_BlMCaI4s2SponLaJuatIz56U236UEwlwTy4_88_AG4RHCMIMSTTc3rMWIMH4EhYoSFEEbo-PCOEaIDcObcGkIaURyfggFhJE5TRobgfV47_bFqXaDr1gTtSgbK2KoreatNHRgVlLrRReAnmIbbVotSup7sqGlaXemvX1s9L6f9h-WN7Lx15-BE8dLJi8M9Aq_3dy-zx3Dx9DCfTRehwBHBYYqTSFGVUE4R5qlIMC-IoNyfPC9YqhDJY4mTlCWE5rjgsVJCFJhFLC2EImQEbva5jTWfnXRtVmknZFnyWprOZQQhHBOIaOTp9R-6Np2t_XZeYUgI9NCr270S1jhnpcoaqytutxmCWV961pee9aV7e3VI7PJKFr_yp2UPJnuw0aXc_p-UvS2ny13kN6I2jUE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120330530</pqid></control><display><type>article</type><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</creator><creatorcontrib>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</creatorcontrib><description>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics. This article is categorized under: Nanotechnology Approaches to Biology &gt; Nanoscale Systems in Biology Biology‐Inspired Nanomaterials &gt; Lipid‐Based Structures LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</description><identifier>ISSN: 1939-5116</identifier><identifier>ISSN: 1939-0041</identifier><identifier>EISSN: 1939-0041</identifier><identifier>DOI: 10.1002/wnan.1992</identifier><identifier>PMID: 39358893</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Animals ; Cholesterol ; Clinical trials ; formulations ; Genetic disorders ; Genetic transformation ; Humans ; Infectious diseases ; lipid nanoparticles ; Lipids ; Lipids - chemistry ; Liposomes ; Medical innovations ; mRNA stability ; mRNA therapeutics ; Nanomaterials ; Nanoparticles ; Nanoparticles - chemistry ; Nanotechnology ; Polyethylene glycol ; RNA, Messenger ; Structural design ; Structural engineering</subject><ispartof>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2024-09, Vol.16 (5), p.e1992-n/a</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</cites><orcidid>0000-0002-2853-2696</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39358893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiao, Xiangyu</creatorcontrib><creatorcontrib>He, Xi</creatorcontrib><creatorcontrib>Qin, Shugang</creatorcontrib><creatorcontrib>Yin, Xiaoling</creatorcontrib><creatorcontrib>Song, Tingting</creatorcontrib><creatorcontrib>Duan, Xing</creatorcontrib><creatorcontrib>Shi, Haixing</creatorcontrib><creatorcontrib>Jiang, Shanhui</creatorcontrib><creatorcontrib>Zhang, Yupei</creatorcontrib><creatorcontrib>Song, Xiangrong</creatorcontrib><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><title>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</title><addtitle>Wiley Interdiscip Rev Nanomed Nanobiotechnol</addtitle><description>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics. This article is categorized under: Nanotechnology Approaches to Biology &gt; Nanoscale Systems in Biology Biology‐Inspired Nanomaterials &gt; Lipid‐Based Structures LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</description><subject>Animals</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>formulations</subject><subject>Genetic disorders</subject><subject>Genetic transformation</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>lipid nanoparticles</subject><subject>Lipids</subject><subject>Lipids - chemistry</subject><subject>Liposomes</subject><subject>Medical innovations</subject><subject>mRNA stability</subject><subject>mRNA therapeutics</subject><subject>Nanomaterials</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Nanotechnology</subject><subject>Polyethylene glycol</subject><subject>RNA, Messenger</subject><subject>Structural design</subject><subject>Structural engineering</subject><issn>1939-5116</issn><issn>1939-0041</issn><issn>1939-0041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10E1LwzAYB_AgipvTg19ACl700C0vbdocx_BlMCaI4s2SponLaJuatIz56U236UEwlwTy4_88_AG4RHCMIMSTTc3rMWIMH4EhYoSFEEbo-PCOEaIDcObcGkIaURyfggFhJE5TRobgfV47_bFqXaDr1gTtSgbK2KoreatNHRgVlLrRReAnmIbbVotSup7sqGlaXemvX1s9L6f9h-WN7Lx15-BE8dLJi8M9Aq_3dy-zx3Dx9DCfTRehwBHBYYqTSFGVUE4R5qlIMC-IoNyfPC9YqhDJY4mTlCWE5rjgsVJCFJhFLC2EImQEbva5jTWfnXRtVmknZFnyWprOZQQhHBOIaOTp9R-6Np2t_XZeYUgI9NCr270S1jhnpcoaqytutxmCWV961pee9aV7e3VI7PJKFr_yp2UPJnuw0aXc_p-UvS2ny13kN6I2jUE</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Jiao, Xiangyu</creator><creator>He, Xi</creator><creator>Qin, Shugang</creator><creator>Yin, Xiaoling</creator><creator>Song, Tingting</creator><creator>Duan, Xing</creator><creator>Shi, Haixing</creator><creator>Jiang, Shanhui</creator><creator>Zhang, Yupei</creator><creator>Song, Xiangrong</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2853-2696</orcidid></search><sort><creationdate>202409</creationdate><title>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</title><author>Jiao, Xiangyu ; He, Xi ; Qin, Shugang ; Yin, Xiaoling ; Song, Tingting ; Duan, Xing ; Shi, Haixing ; Jiang, Shanhui ; Zhang, Yupei ; Song, Xiangrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>formulations</topic><topic>Genetic disorders</topic><topic>Genetic transformation</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>lipid nanoparticles</topic><topic>Lipids</topic><topic>Lipids - chemistry</topic><topic>Liposomes</topic><topic>Medical innovations</topic><topic>mRNA stability</topic><topic>mRNA therapeutics</topic><topic>Nanomaterials</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Nanotechnology</topic><topic>Polyethylene glycol</topic><topic>RNA, Messenger</topic><topic>Structural design</topic><topic>Structural engineering</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiao, Xiangyu</creatorcontrib><creatorcontrib>He, Xi</creatorcontrib><creatorcontrib>Qin, Shugang</creatorcontrib><creatorcontrib>Yin, Xiaoling</creatorcontrib><creatorcontrib>Song, Tingting</creatorcontrib><creatorcontrib>Duan, Xing</creatorcontrib><creatorcontrib>Shi, Haixing</creatorcontrib><creatorcontrib>Jiang, Shanhui</creatorcontrib><creatorcontrib>Zhang, Yupei</creatorcontrib><creatorcontrib>Song, Xiangrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiao, Xiangyu</au><au>He, Xi</au><au>Qin, Shugang</au><au>Yin, Xiaoling</au><au>Song, Tingting</au><au>Duan, Xing</au><au>Shi, Haixing</au><au>Jiang, Shanhui</au><au>Zhang, Yupei</au><au>Song, Xiangrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics</atitle><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle><addtitle>Wiley Interdiscip Rev Nanomed Nanobiotechnol</addtitle><date>2024-09</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>e1992</spage><epage>n/a</epage><pages>e1992-n/a</pages><issn>1939-5116</issn><issn>1939-0041</issn><eissn>1939-0041</eissn><abstract>mRNA‐based therapeutics increasingly demonstrate significant potential in treating various diseases, including infectious diseases, cancers, and genetic disorders. Effective delivery systems are crucial for advancing mRNA therapeutics. Lipid nanoparticles (LNPs) serve as an excellent carrier, widely validated for their safety and tolerability in commercially available mRNA vaccines. Standard LNPs typically consist of four components: ionizable lipids (ILs), helper lipids, cholesterol, and polyethylene glycol‐lipids (PEG‐lipids), with the structural design of ILs gradually becoming a focal point of research interest. The chemical structures and formulations of the other components also significantly affect the delivery efficiency, targeting specificity, and stability of LNPs. The complex formulations of LNPs may hinder the clinical transformation of mRNA therapeutics and have raised widespread concerns about their safety. This review aims to summarize the progress of LNPs‐based mRNA therapeutics in clinical trials, focusing on adverse effects that occurred during these trials. It also discusses representative innovations in LNP components, highlighting challenges and potential ways in this research field. We firmly believe this review will promote further improvements and designs of LNP compositions to optimize mRNA therapeutics. This article is categorized under: Nanotechnology Approaches to Biology &gt; Nanoscale Systems in Biology Biology‐Inspired Nanomaterials &gt; Lipid‐Based Structures LNP‐based mRNA therapeutics have been extensively used to treat a range of diseases. Optimizing the components of LNPs can enhance the efficacy and safety of mRNA drugs.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>39358893</pmid><doi>10.1002/wnan.1992</doi><tpages>21</tpages><orcidid>https://orcid.org/0000-0002-2853-2696</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1939-5116
ispartof Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2024-09, Vol.16 (5), p.e1992-n/a
issn 1939-5116
1939-0041
1939-0041
language eng
recordid cdi_proquest_miscellaneous_3112530164
source Wiley-Blackwell Read & Publish Collection
subjects Animals
Cholesterol
Clinical trials
formulations
Genetic disorders
Genetic transformation
Humans
Infectious diseases
lipid nanoparticles
Lipids
Lipids - chemistry
Liposomes
Medical innovations
mRNA stability
mRNA therapeutics
Nanomaterials
Nanoparticles
Nanoparticles - chemistry
Nanotechnology
Polyethylene glycol
RNA, Messenger
Structural design
Structural engineering
title Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20formulation%20of%20lipid%20nanoparticles%20for%20the%20optimization%20of%20mRNA%20therapeutics&rft.jtitle=Wiley%20interdisciplinary%20reviews.%20Nanomedicine%20and%20nanobiotechnology&rft.au=Jiao,%20Xiangyu&rft.date=2024-09&rft.volume=16&rft.issue=5&rft.spage=e1992&rft.epage=n/a&rft.pages=e1992-n/a&rft.issn=1939-5116&rft.eissn=1939-0041&rft_id=info:doi/10.1002/wnan.1992&rft_dat=%3Cproquest_cross%3E3120330530%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2432-8274f6f76a612a8c72ad3c6aaaabbd98f13b5e2789736b2da5ffccd29498dcf33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120330530&rft_id=info:pmid/39358893&rfr_iscdi=true